CAR-T therapy is a breakthrough therapy that uses patients’ immune cells to treat certain advanced blood cancers. The therapy is very expensive and can have a list price of $450,000 per patient.
The pharmaceutical industry, patients advocates and hospitals have said Medicare’s low reimbursement rates for CAR-T therapies have forced hospitals to choose between losing money or not giving the therapy to patients at all, STAT reported.
Under the current reimbursement system, hospitals are losing about $50,000 per patient every time they administer a CAR-T therapy, according to an analysis from the American Action Forum cited by STAT.
Medicare bases its reimbursement rates for CAR-T on the average cost for a complicated bone marrow transplant, an amount far lower than what CAR-T therapies actually cost.
The new proposed payment policy would reimburse hospitals for CAR-T drugs based on the average price of the two CAR-T therapies currently on the market, Gilead’s Yescarta, a non-Hodgkin lymphoma treatment, and Novartis’ Kymriah, a leukemia treatment.
Read the full article here.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
